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Enhanced immunogenicity of subunit antigens can be achieved by antigen encapsulation in liposomes
and the addition of immune potentiators. In this study we co-encapsulated ovalbumin (OVA) and a Toll-
like receptor (TLR) ligand (PAM3CSK4 (PAM) or CpG) in cationic liposomes and investigated the effect of
the formulations on dendritic cell (DC) maturation in vitro and on the immune response in mice after
intradermal immunisation. Co-encapsulation of PAM did not affect the OVA content of the liposomes, but
co-encapsulation of CpG led to a decrease in OVA content by 25%. After liposomal encapsulation, both
ligands retained the ability to activate TLR-transfected HEK cells, though PAM only induced activation atntradermal vaccination
iposomes
LR ligands
elevated concentrations. DC maturation induced by liposome-based adjuvant formulations was superior
compared to the free adjuvants. Encapsulationof PAMandCpG in liposomesdidnot inﬂuence the total IgG
titres compared to the antigen/adjuvant solution, but OVA/CpG liposomes shifted the IgG1/IgG2a balance
more to the direction of IgG2a compared to non-encapsulated CpG. Moreover, only this formulation
resulted in IFN- production by restimulated splenocytes from immunised mice. These data show that
en an
intraco-encapsulation of antig
response generated after
. Introduction
Vaccines should be capable of eliciting a strong and protective
mmune response, but are also required to be safe. Subunit antigens
re regarded safer than live-attenuated and inactivated pathogens,
ut lack strong immunogenicity. Optimising the formulation of
ubunit vaccines could be instrumental in improving the immuno-
enicity and therefore in the development of safe and effective
accines [1]. Approaches to achieve a higher efﬁcacy include opti-
ising thedelivery to and interactionwithdendritic cells (DCs) and
he addition of immune potentiators to improve the activation of
hese DCs.
Lessons to improve the interactionwithDCs canbe learned from
ature, as all pathogens are particulates. Particles are better taken
p by DCs and may provide an additional beneﬁt by offering pro-
onged antigen delivery due to slow antigen release [2]. Liposomes
re elegant and ﬂexible nanoparticulates that have been used for a
ong time as drug delivery systems. Actually, when they were used
or the ﬁrst time in the pharmaceutical ﬁeld in 1974, it was for the
eliveryof vaccines [3]. Since then theyhavebeenused successfully
or the delivery of protein antigens [4–6] andDNAvaccines [7,8]. By
∗ Corresponding author at: Division of Drug Delivery Technology, Lei-
en/AmsterdamCenter for Drug Research, Gorlaeus Laboratories, LeidenUniversity,
O Box 9502, 2300 RA Leiden, The Netherlands. Tel.: +31 71 527 4208.
264-410X © 2010 Elsevier Ltd. 
oi:10.1016/j.vaccine.2010.11.061
Open access under the Elsevier OA license.d immunepotentiator in cationic liposomes, can affect the type of immune
dermal immunisation.
© 2010 Elsevier Ltd. 
changing the lipid composition of liposomes, their characteristics
can be varied. The usage of positively charged lipids, for instance,
creates cationic liposomes. It has become clear that cationic lipo-
somes are one of the most effective liposomal delivery systems for
antigens to antigen presenting cells [9–12].
Liposomes themselves may function as an adjuvant by improv-
ing the uptake of antigens by DCs, but generally lack intrinsic
immune-stimulatory effects [11,13]. By co-encapsulation of an
immune potentiator, the immunogenicity of liposomes can be
improved. As classiﬁed by Schijns [14], immune potentiators
(i) interact with pattern recognition receptors (PRRs) (Signal 0)
[15,16]; (ii) are co-stimulatory molecules necessary for activating
naïve T cells (Signal 2) or (iii) act as a ‘danger-signal’ [17]. Pathogens
express speciﬁc pathogen-associated molecular patterns (PAMPs)
that are recognised by PRRs, of which the Toll-like receptors (TLRs)
are an important subclass. All cells, but mainly antigen present-
ing cells such as DCs, have TLRs that recognise speciﬁc ligands. In
humans11differentTLRshavebeen identiﬁed, themajorityof them
being speciﬁc for microbial products. Most TLRs are present on the
cell surface, but TLRs that recognise nucleic acids (TLR3, 7, 8 and 9)
are located intracellularly [18].
Open access under the Elsevier OA license.In this study we co-encapsulated a model antigen, ovalbumin
(OVA) and two TLR ligands in cationic liposomes. The selected
TLR ligands are Pam3CSK4, a synthetic lipoprotein consisting of a
tri-palmitoyl-S-glyceryl cysteine lipopeptide with a pentapeptide
SKKKK (PAM), and unmethylated CpG oligonucleotide (CpG). PAM
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s recognised by TLR2 in association with TLR1, both cell surface
xpressed receptors. CpG is a TLR9 ligand,which is expressed intra-
ellularly. By co-encapsulation in liposomes it is ensured that both
he antigen and the immune potentiator are co-delivered to the
Cs,which is considered essential for induction of a strong immune
esponse [19–21]. To examine the effect of co-encapsulation, a
omparison was made to solutions of OVA mixed with the respec-
ive TLR ligands. The formulations were tested in vitro for their
C-stimulating properties and their immunogenicity was studied
n vivo by intradermal (ID) injection, an immunisation route which
as regained interest in recent years due to the dose-sparing poten-
ial compared to intramuscular immunisation [22–25].
. Materials and methods
.1. Materials
Soybean phosphatidylcholine (PC), 1,2-dioleoyl-3-
rimethylammonium-propane chloride salt (DOTAP) and
,2-dioleoyl-sn-glycero-3-ghosphoethanolamine (DOPE) were
indly provided by Lipoid GmbH (Ludwigshafen, Germany).
valbumin grade VII was obtained from Calbiochem (Merck
GaA, Darmstadt, Germany). FITC-labelled ovalbumin (OVAFITC)
as purchased from Invitrogen (Breda, The Netherlands). PAM,
hodamine-labelled PAM, CpG 2006 and 1826 and their FITC-
abelled analogues were purchased from Invivogen (Toulouse,
rance). Horseradish peroxidase (HRP)-conjugated goat anti-
ouse IgG ( chain speciﬁc), IgG1 (1 chain speciﬁc) and IgG2a
2a chain speciﬁc) were purchased from Southern Biotech (Birm-
ngham, USA). Chromogen 3,3’′,5,5′-tetramethylbenzidine (TMB)
nd the substrate buffer were purchased from Invitrogen. All
ell culture media, including serum and trypsin were purchased
rom Gibco (Invitrogen). Nimatek® (100mg/ml Ketamine, Eurovet
nimal Health B.V., Bladel, The Netherlands), Oculentum Simplex
Farmachemie, Haarlem, The Netherlands), Rompun® (20mg/ml
ylazine, Bayer B.V., Mijdrecht, The Netherlands) and the injection
uid (0.9% NaCl) were obtained from a local pharmacy. Phosphate
uffered saline (PBS) pH 7 was obtained from Braun (Oss, The
etherlands). All other chemicals were of analytical grade.
.2. Animals
Female BALB/c mice (H2d), 8-weeks old at the start of the vac-
ination study were purchased from Charles River (Maastricht, The
etherlands), andmaintainedunder standardised conditions in the
nimal facility of the Leiden/Amsterdam Center for Drug Research,
eiden University. The study was carried out under the guidelines
ompiled by the Animal Ethic Committee of the Netherlands.
.3. Liposome preparation and characterization
Liposomes with a lipid:OVA:TLR ligand ratio of 50:1:2 (w/w)
ere prepared using the ﬁlm hydration method [26] followed
y extrusion. Soy-derived phosphatidyl choline (PC), dioleoyl
rimethyl ammonium propane (DOTAP) and dioleoyl phosphatidyl
thanolamine (DOPE), dissolved in chloroform, were mixed in a
:1:1 molar ratio in a ﬂask. A thin lipid ﬁlm was formed at the bot-
om of this ﬂask using a rotary evaporator. The residual organic
olvent was removed by nitrogen ﬂow. The ﬁlm was rehydrated
n a 10mM phosphate buffer pH 7.4 (7.7mM Na2HPO4 and 2.3mM
aH2PO4) containing1mg/mlOVA.Theﬁnal concentrationof lipids
as 5% (w/v). The dispersion was shaken in the presence of glass
eads at 200 rpm for 2h at room temperature. To obtain monodis-
erse liposomes, the dispersion was extruded (LIPEXTM extruder,
orthernLipids Inc., Canada)4 times throughacarbonateﬁlterwith
pore size of 400nm and 4 times through a ﬁlter with a pore size of (2011) 1045–1052
200nm (Nucleopore Millipore, Amsterdam, The Netherlands). For
co-encapsulation of a TLR ligand, after hydration either PAMor CpG
was added to aﬁnal concentrationof 2mg/ml. Thedispersionswere
dehydrated by freeze-drying and subsequently rehydrated in the
same buffer solution to encapsulate the TLR ligands [27]. Extrusion
was performed as described above.
The size and zetapotential of the liposomes were determined
by dynamic light scattering and laser Doppler velocimetry, respec-
tively, using a Zetasizer® Nano ZS (Malvern Instruments, UK). The
amount of OVA, PAM and CpG present in the liposomes was deter-
mined by using their ﬂuorescently labelled analogues (10% of used
OVA, PAM or CpG were labelled). The free antigen and TLR ligand
were separated from the liposomes by ﬁltration using a Vivaspin
2 centrifugal concentrator (PES membrane, MWCO 300kDa, Sar-
torius Stedim, Nieuwegein, The Netherlands) and quantiﬁed using
a FS920 ﬂuorimeter (Edinburgh Instruments, Campus Livingston,
UK). The stability of the OVA-loaded liposomes and OVA release
from the liposomes was determined in PBS pH 7.4. Liposomes con-
taining OVAFITC were diluted to a 0.5% lipid concentration and
stored at 37 ◦C under constant stirring. Samples were taken at
selected time intervals and the size of the liposomes and antigen
encapsulation were measured after ﬁltration.
2.4. Activity of TLR ligands
HEK293cells, stably transfectedwithhumanCD14/TLR2or TLR9
and a NF-B inducible IL-8 (TLR2) or luciferase (TLR9) plasmid
[28,29], were maintained in Dulbecco’s Modiﬁed Eagle Medium
(DMEM), supplemented with 10% fetal calf serum (FCS), 1mM
sodium pyruvate and 10g/ml ciproﬂoxacin. To the HEK293-
CD14/TLR2 cells 5g/ml puromycin and to the HEK293/TLR9 cells
700g/ml Geneticin (G418) was added as a selection marker. For
stimulation experiments, both cell types were seeded at a density
of 4.0×104 cells/well in 96-well ﬂat bottom plates and stimulated
the next day. The cells were stimulated with the formulations con-
taining different concentrations of PAM (maximum 450ng/ml) or
CpG (maximum10g/ml).Mediumwas used as a negative control.
TLR2 stimulation was measured by determining the IL-8 produc-
tion in supernatants after 24h using a commercial kit (Sanquin,
Amsterdam, The Netherlands), following the manufacturer’s rec-
ommendations. The HEK-293/TLR9 cells were stimulated for 6h
with the formulations. The luciferase expression was determined
with a luciferase assay kit (Promega, Leiden, The Netherlands)
according to the manufacturer’s manual, using a DLReady Berthold
Centro XS luminometer (Berthold Detection Systems, Germany).
2.5. DC activation
Monocytes were isolated from human donor blood before
each experiment by Ficoll and Percoll density centrifugation
and depletion of platelets was performed by surface adher-
ence of the monocytes in 24-well plates (Corning, Schiphol, The
Netherlands) as described previously [30]. The monocytes were
cultured for 6 days at 37 ◦C and 5% CO2 after seeding at a den-
sity of 0.5×106 cells/well in RPMI 1640, supplemented with 10%
(v/v) FCS, 2mM glutamine, 1mM sodium pyruvate and 500U/l
penicillin/streptomycin. To differentiate monocytes into immature
DCs 250U/ml granulocyte macrophage-colony stimulating factor
(GM-CSF) and 100U/ml IL-4 (Invitrogen) was added. Medium was
refreshed after 3 days.
DC were incubated for 48h at 37 ◦C in RPMI 1640 contain-
ing 500U/ml GM-CSF with OVA (highest concentration 5g/ml),
either freeor encapsulated into liposomeswithandwithout PAMor
CpG (highest concentration 10g/ml), keeping the lipid:OVA:TLR
ligand ratio 50:2:1 (w/w). OVA, OVA liposomes and mixtures of
OVA with PAM or OVA with CpG were used as controls and LPS
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Table 1
Characteristics of liposomal formulations. All data are averages± SD of at least 3 different batches.
Size [nm] PDI ZP [mV] LE OVA [%] LE TLR ligand [%]
OVA liposomes 130 ± 10 0.19 ± 0.03 23 ± 1 98 ± 2 –
P
(
w
m
o
(
e
c
i
o
2
s
a
s
s
w
5
m
s
f
t
v
b
w
(
t
T
2
d
p
t
t
w
a
o
a
2
w
s
s
C
d
4
t
a
w
a
and CpG
PAM and CpG are two TLR ligands. The effect of ligand encap-
sulation in OVA liposomes on their interactions with the TLRs was
studied on HEK293 cells transfected with either TLR2 (receptor forOVA/PAM liposomes 128 ± 9 0.25 ± 0.01
OVA/CpG liposomes 263 ± 22 0.30 ± 0.09
DI =polydispersity index, ZP= zetapotential, LE = loading efﬁciency.
100ng/ml, Invivogen) was added as a positive control. Cells were
ashed 3 times with PBS containing 1% (w/v) bovine serum albu-
in and 2% (v/v) FCS and incubated for 30min with a mixture
f 20× diluted anti-HLADR-FITC, anti-CD83-PE and anti-CD86-APC
Becton Dickinson) in the dark at 4 ◦C. Cells were washed and the
xpression of MHCII, CD83 and CD86 was quantiﬁed using ﬂow
ytometry (FACSCanto II, Becton Dickinson) relative to LPS, assum-
ng100%maturation for LPS-treatedDC. Live cellswere gated based
n forward and side scatter.
.6. Intradermal immunisation
Groups of 8 mice were immunised with the OVA-loaded lipo-
omes with and without PAM or CpG by ID injection into the
bdominal skin as describedpreviously [30]. Besides the liposomes,
olutions of OVA or OVA with PAM or CpG in PBS were injected and
ubcutaneous (SC) injection of OVA served as a control. The mice
ere vaccinated twice with three weeks intervals with a dose of
g OVA and 10g PAM or CpG in a total volume of 30l. To
aintain this ratio between antigen and immune potentiator, lipo-
omes used for the immunisation studywere not ﬁltered to remove
ree antigen and TLR ligand. Blood samples were collected from the
ail vein 1 day before each immunisation. Threeweeks after the last
accination the mice were sacriﬁced. Just before euthanasia total
loodwascollected fromthe femoral artery.Afterwards the spleens
ere removed. Blood sampleswere collected inMiniCollect® tubes
Greiner Bio-one, Alphen a/d Rijn, The Netherlands) till clot forma-
ion and centrifuged 10min at 10,000× g to obtain cell-free sera.
he sera were stored at −80 ◦C until further use.
.7. Detection of IgG, IgG1 and IgG2a
OVA speciﬁc antibodies (IgG, IgG1 and IgG2a) in the sera were
eterminedby sandwichELISAasdescribedpreviously [30]. Brieﬂy,
lates were coated overnight with 100ngOVA/well. After blocking,
wo-fold serial dilutions of sera from individual mice were applied
o the plates. HRP-conjugated antibodies against IgG, IgG1 or IgG2a
ere added and detected by TMB. Antibody titres were expressed
s the reciprocal of the sample dilution that corresponds to half
f the maximum absorbance at 450nm of a complete s-shaped
bsorbance-log dilution curve.
.8. T cell activation
The spleens from immunised mice were maintained in RPMI
ith 10% FCS, 50M -mercaptoethanol, 2mM glutamine, 1mM
odium pyruvate and 500U/l penicillin/streptomycin. Cell suspen-
ionswereobtainedusing a cell strainer (70m,BectonDickinson).
ells were washed and cultured in 96-well ﬂat bottom plates at a
ensity of 2.0×105 cells/well in triplicate and restimulated with
0g/ml OVA. ConA (Sigma–Aldrich) 5g/ml was used as a posi-
ive control.After3days the supernatantswerecollectedandstored
t −80 ◦C until further use. The amount of IFN- in the supernatant
asdeterminedbyELISAusingacommercial kit (BectonDickinson)
ccording to the manufacturer’s instructions.20 ± 2 96 ± 3 85 ± 4
18 ± 2 72 ± 5 61 ± 6
2.9. Statistics
Statistical analysis was performed with Prism 5 for Windows
(Graphpad, SanDiego,USA). Statistical signiﬁcancewasdetermined
either by a oneway or a twoway analysis of variance (ANOVA)with
a Bonferroni post-test, depending on the experiment set-up.
3. Results
3.1. Liposome characteristics
With the ﬁlm hydration method and subsequent extrusion,
OVA-containing liposomes with an average size of 130nm and a
positive zetapotential could be prepared in a reproducible manner
(Table 1). Ultraﬁltration showed that nearly 100% OVA was associ-
ated with the liposomes. PAM could be easily incorporated into the
liposomes (∼85%) and the incorporation did not affect the (mea-
sured) liposome characteristics. The addition of CpG did inﬂuence
the liposome characteristics as the size augmented by two-fold.
Furthermore, CpG reduced OVA association with the liposomes,
probably due to competition between the antigen and the TLR lig-
and as both compounds bear a negative charge.
The stability and release of the OVA liposomes was studied over
time in PBS at 37 ◦C. Dilution in PBS had an initial effect on the
size of the liposomes as their size decreased from 130nm to 90nm,
due to the inﬂuence of PBS on the hydrodynamic diameter of the
liposomes [31]. After this initial size decrease, the size remained
stable during the following 8 days (Fig. 1). During this period OVA
was released from the liposomes. An initial burst release of 25%was
observed and after 5h already 50% of theOVAwas no longer associ-
atedwith the liposomes. During the following 8 days the remaining
OVA was slowly released.
3.2. Preservation of TLR-activation of liposome encapsulated PAMFig. 1. Size and OVA release of OVA liposomes over time in PBS (pH 7.4) at 37 ◦C.
Mean± SEM of 3 individual batches.
1048 S.M. Bal et al. / Vaccine 29 (2011) 1045–1052
Fig. 2. Preservation of TLR-activating capacity of encapsulated TLR ligands tested onHEK293 cells transfectedwith TLR2 or TLR9. (A) Ability of OVA/PAM liposomes and a PAM
solution to activate TLR2-transfected HEK-293 cells; (B) ability of OVA/CpG liposomes and a CpG solution to activate TLR9-transfected HEK-293 cells. Data are mean± SEM
of 3 different experiments.
Fig. 3. Representative examples of FACS plots of the expression of CD86 on DCs after incubation with medium (A), OVA (B), OVA liposomes (C), LPS (D), OVA+PAM (E),
OVA/PAM liposomes (F), OVA+CpG (G) and OVA/CpG liposomes (H). Horizontal bars represent mean ﬂuorescence intensity.
S.M. Bal et al. / Vaccine 29 (2011) 1045–1052 1049
F d OVA
( expres
e
P
s
s
t
P
t
l
d
n
b
(
3
i
f
a
n
c
e
5
(
t
lig. 4. Upregulation of DC maturation markers by OVA/PAM liposomes (A–C) an
w/w). M=medium and the concentrations are expressed in g/ml. The values are
xperiments). *p<0.05, **p<0.01, ***p<0.001.
AM) or TLR9 (receptor for CpG). Non-adjuvanted liposomes and a
olution of OVA did not induce TLR2 or TLR9 activation (data not
hown). PAM in solutionwas a stronger TLR2 activator compared to
he liposome encapsulated PAM (Fig. 2A). A 15-fold higher dose of
AMwasnecessary to obtain the same level of IL-8 production from
he HEK293-CD14/TLR2 cells. Both PAM in solution and OVA/PAM
iposomes activated the cells in a concentrationdependentmanner.
CpG activated TRL9-transfected HEK cells in a concentration
ependent way as well. Encapsulation of CpG in liposomes did
ot affect its ability to activate TLR9, as no difference in activation
etween a solution of CpG and OVA/CpG liposomes was observed
Fig. 2B).
.3. Liposomes with encapsulated TLR ligand activate DCs
DCs express TLRs which upon stimulation with TLR ligands
nduces the expression of maturation markers on the DC’s sur-
ace as shown for CD86 in Fig. 3. Whereas application of OVA
nd OVA liposomes (maximum OVA concentration 5g/ml) did
ot stimulate the DCs, encapsulation of both TLR ligands had a
lear effect on the DC activation. Application of 10g/ml PAM
ncapsulated in OVA-containing liposomes (OVA concentration
g/ml) signiﬁcantly elevated the MHCII and CD83 expression
p<0.01) compared to untreated cells and this activation proved
o be concentration dependent (Fig. 4A and B). Moreover, a simi-
ar pattern was observed for the CD86 levels. After application of a/CpG liposomes (D–F). The liposomes had a lipid:OVA:TLR ligand ratio of 50:1:2
sed as mean ﬂuorescence intensity (MFI)± SEM relative to LPS (n=6, two separate
PAM solution also a trend of elevated MHCII and CD83 levels was
observed, but these levels were not signiﬁcantly higher compared
to untreated DCs. PAM had a minor effect on the CD86 expression
(Fig. 4C).
The effect of CpGencapsulationwasmorepronounced.Whereas
a CpG solution did not activate the DCs at all, encapsulation of CpG
in liposomes induced increased MHCII, CD83 and CD86 expression
(Fig. 4D–F). The level of expression obtained with the highest CpG
concentration was comparable to that induced by LPS, the positive
control.
3.4. Intradermal vaccination with liposomal formulations
To investigate whether the improved DC activation ability in
vitro correlated with the immunogenicity in mice, an immunisa-
tion studywasperformed. The liposomal formulations andphysical
mixtures of OVA with CpG or PAM were applied ID. Both the OVA-
speciﬁc total serum IgG titres (Fig. 5A) and the antibody subclass
(IgG1 and IgG2a, Fig. 5B) were measured.
The addition of either PAM or CpG into liposomes signiﬁ-
cantly increased the immunogenicity of OVA-loaded liposomes
(p<0.05), which did not enhance the immune response compared
to an OVA solution. Incorporation of the TLR ligands in OVA-
containing liposomes induced similar IgG titres as compared to
the physical mixtures of OVA and the TLR ligand. However, the
liposomes did inﬂuence the IgG1/IgG2a balance of the immune
1050 S.M. Bal et al. / Vaccine 29 (2011) 1045–1052
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inclusion of immune potentiators into liposome-based formula-
tions will therefore be necessary to improve their application in
vaccination strategies.ig. 5. OVA speciﬁc IgG titres in serum after a prime and subsequent booster imm
ean± SD of 8 mice. (C) Corresponding IgG1/IgG2a ratios of individual mice. Non-re
igher than ID OVA; ‡signiﬁcantly higher than ID OVA liposomes; *p<0.05, **p<0.0
esponse (Fig. 5B/C). The main IgG subtype induced by plain
VA was IgG1. The addition of PAM resulted in equally elevated
gG1 and IgG2a levels upon ID immunisation. Encapsulation of
VA alone in liposomes and co-encapsulation of OVA and PAM
esulted in a tendency of altering the balance more towards IgG2a
Fig. 5B/C). Co-administration of CpGwithOVA signiﬁcantly shifted
he IgG1/IgG2abalance towards IgG2a (p<0.05). This alterationwas
ven more pronounced when OVA and CpG were co-encapsulated
n liposomes (p<0.001).
Besides the humoral immune response, the effect of the dif-
erent formulations on the cellular immunity was investigated by
easuring the IFN- production by restimulated splenocytes. Th1
ells produce IFN- which is reported to induce isotype switch-
ng and IgG2a production [32,33]. In agreement with the antibody
ubclass titres, only formulations containing CpG, which resulted
n the highest IgG2a titres, induced the production of measurable
FN- levels and these levels were the highest for mice receiving
VA/CpG liposomes (p<0.05, Fig. 6).
. Discussion
Liposomes are an attractive delivery system for vaccines as they
rotect the antigen from degradation, opsonise the uptake of the
ncapsulated antigen by DCs and provide controlled release of the
ntigen over time. Moreover, it is a versatile system that permits
he inclusion of various immune potentiators. This is reﬂected by
he fact that high encapsulation efﬁciencies of both PAM and CpG
ere achieved, whereas both TLR ligands have very different phys-
cal chemical characteristics. This is an important feature, as in line
ith other reports [11,13], this study shows that cationic liposomestion (A) and IgG1 (white bars) and IgG2a (black bars) after the second boost (B).
ers for IgG1 or IgG2a were excluded. Bar represents geometric mean. †Signiﬁcantly
<0.001
themselves are not that immunogenic; OVA loaded liposomes did
not enhance the antibody response compared to free OVA. TheFig. 6. IFN- production by splenocytes after restimulation with OVA. Mean+SEM
of 5 mice are shown. *p<0.05.
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Here we showed that co-encapsulation of antigens and TLR
igands in liposomes can enhance antigen delivery in vitro and com-
ine this with potent stimulation of the innate immune response
s can be concluded from the vaccination study with PAM- or
pG-containing liposomes. The anti-OVA serum IgG titres after
he prime and booster vaccinations with these adjuvanted formu-
ations were signiﬁcantly higher than those obtained with plain
iposomes or OVA. Interestingly, the IgG titres elicited in mice vac-
inated with a physical mixture of OVA and PAM or CpG, were
omparablewith those elicited by those thatwere immunisedwith
AM- or CpG-adjuvanted liposomes. This is in accordancewith pre-
ious studies by us and other groups, where no additional effect of
iposomes on the IgG titres was observed after vaccination via dif-
erent routes [11,13,34]. It not only holds true for liposomes, but
lso for antigen-loaded N-trimethyl chitosan nanoparticles [30].
his raises questions regarding the usefulness of nanoparticles for
D immunisation.However, IgG titres not necessarily correlatewith
rotection and are therefore not the only parameter to express the
xtent or quality of an immune response. A cellular response,which
an be measured by the production of IgG2a antibodies and IFN-
roduction by T-cells, can sometimes be more predictive [35]. The
resent study shows that liposomes did inﬂuence the quality of
he immune response. A trend of higher IgG2a levels compared to
ntigen and TLR ligand solutions was observed for all three lipo-
omal formulations. Similar results were also reported by Brgles
t al. after SC immunisation; OVA-containing liposomes were able
o modulate the immune response towards a Th1/CD8+ cytotoxic T
ymphocyte (CTL) direction, without inﬂuencing the overall inten-
ity of the immune response [13].
How liposomesmodify the quality of the response remains to be
lariﬁed. The in vitro DC study clearly demonstrates that CpG, and
o a lesser extent also PAM, needs to be encapsulated to activate
he DCs. This is in accordance with a study by Fernandes et al. who
howed that the liposomal incorporation of two other triacylated
ipopeptidesenhanced theproliferationofmurine splenocytes [36],
hich could be attributed to improved adjuvant uptake by the DCs
20,21]. The prominent advantage of liposomal encapsulation of
pG correlates excellently with the cellular localisation of the PAM
nd CpG receptors. Whilst TLR2 is expressed on the cell surface,
LR9 is present in the endosomal compartment. Conceivably, CpG
roﬁts more from liposomal delivery than PAM. For PAM this is
llustrated in vitro as liposome encapsulation decreases its abil-
ty to stimulate HEK293-CD14/TLR2 cells, probably due to reduced
nteraction with the receptor. It is known that liposomal incorpo-
ation can have a profound inﬂuence on the immunomodulatory
roperties of lipoproteins [37]. PAM’s functionality is dependent
n different structural components. The peptide segment linked
o the carboxyl terminus of the palmitoyl lipopeptide, the SKKKK
equence, was shown to elevate the adjuvant activity compared to
ther peptide sequences [38]. Changes to the lipopeptide fatty acid
hains, the O-linked fatty acids in particular, appear to have a sub-
tantial effect on the signalling through TLRs. The palmitoyl groups
C16) provide better adjuvant activity than longer and shorter fatty
cids [39,40]. If the interaction of either of these moieties with the
LR2 is disturbed, the adjuvanticity will be diminished. Liposomal
ncapsulation can also have a positive effect on the adjuvantic-
ty as it improves the solubility of PAM [41] and the DC uptake of
VA,whichmay improveDCmaturation.However, probablydue to
oss of interaction with the TLR2, this did not enhance the immune
esponse in vivo.
For CpG, improved DC uptake of OVA/CpG liposomes facilitates
he interaction with the endosomal TLR9 [18,42], thereby induc-
ng DC maturation. The in vivo situation is more complicated. Even
hough the DCs will preferentially take up the liposomes, the speed
nd duration of antigen and immune potentiator exposure will dif-
er between the solution and the liposomal formulations. CpG and
[
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OVA in solutionwill probably reach the lymphnodes faster than the
liposomes, but only liposomes ensure uptake of CpG and OVA by
the same DC, which was reported to inﬂuence the type of immune
response generated [21]. Indeed, the enhanced DC uptake does
result in a more Th1-biased response, which is most pronounced
for the CpG-containing liposomes. Similar results were reported by
Gursel et al., who showed that co-encapsulation of OVA and CpG in
cationic liposomes induced elevated IgG2a titres and IFN- secre-
tion compared to free CpG after intraperitoneal injection [43]. It
has to be noted that liposome size also affects the Th1/Th2 bias;
larger liposomes tend to induce a Th1 shift [44,45]. As OVA/CpG
liposomes are larger this may further shift the immune response
towards Th1.
Finally the bias towards a more cellular response by the lipo-
somes could also be attributed to the presence of DOPE in the
liposomes. DOPE, a neutral pH-sensitive lipid, is capable of improv-
ing delivery of CpG into the cytosol following APC uptake [46].
Endosomal escape is crucial for MHC I presentation of the antigen
and the induction of CTL responses. It has been reported that lipo-
somes complexed with antigen and either CpG or poly(I:C), which
binds to TLR3 that is also expressed intracellularly, are capable of
cross priming CD8+ T cells [47]. Whether this is also the case after
ID immunisationwith our liposomes requires further investigation,
but the elevated IFN- production is a ﬁrst indication that a CTL
response could be induced [48].
In conclusion, the advantage of co-encapsulation of antigen
and TLR ligand in cationic liposomes is their potency to steer the
immune bias. This depends on the type of TLR ligand used, as
CpG, binding to the intracellular TLR9, induced the production
of IgG2a antibodies and a potent cellular immune response after
ID immunisation, whereas PAM, ligand of extracellular TLR2, did
not.
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